Treatment Options

 Revolutionary Breakthrough: Lithium Orotate

The August 2025 Nature study revealed that endogenous lithium is dynamically regulated in the brain and contributes to cognitive preservation during aging. Lithium was the only metal significantly reduced in the brain in individuals with mild cognitive impairment. Yankner's team found that lithium orotate is effective at one-thousandth the dose of lithium carbonate used for bipolar disorder, with mice showing complete reversal of memory loss and no evidence of toxicity

 Leqembi (lecanemab) was converted from accelerated to traditional FDA approval and works by reducing amyloid plaques. In the CLARITY AD trial with 1,795 participants, it demonstrated   significant reduction of decline, though it carries a boxed warning for amyloid-related imaging abnormalities (ARIA) Mass GeneralPubMed Central. 

Kisunla (Donanemab)

Amyloid-targeting therapy is administered by IV infusion and guided by amyloid PET imaging and biomarker analysis.

Aducanumab was discontinued by its manufacturer (Biogen) in 2024 for commercial reasons, despite being the first therapy to demonstrate amyloid removal benefits 

We take a multidisciplinary approach to patient care, working closely with other healthcare providers to ensure the best possible outcomes. Our team includes neurologists, Psychiatrists, neuropsychologists, and other specialists.

We provide personalized care to all of our patients, taking the time to understand their individual needs and concerns. Our team of experts will work with you to develop a treatment plan that is tailored to your specific needs.

 Donepezil is a centrally acting, reversible acetylcholinesterase inhibitor that increases acetylcholine availability at synapses. While it cannot alter disease progression, it provides modest benefits in cognition and behavior in controlled studies Wiley Online Library. Other established treatments include galantamine and rivastigmine (cholinesterase inhibitors) for mild-to-moderate disease, and memantine (NMDA receptor antagonist) for moderate-to-severe Alzheimer's that regulates glutamate activity  

 Lithium orotate shows the most promise for comprehensive disease modification with excellent safety Anti-amyloid treatments provide modest but statistically significant benefits with safety concerns Traditional medications offer symptomatic relief but don't modify disease progression Future approach will likely combine multiple mechanisms for optimal outcomes  The research suggests that lithium deficiency may be a fundamental early trigger of Alzheimer's, making lithium orotate supplementation potentially the most transformative treatment approach discovered to date.